Navidea Biopharmaceuticals Announces Positive Top-Line Results from Interim Analysis of Lymphoseek® Phase 3 Clinical Trial in Head and Neck Cancer Apr 4, 2013
Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical Trial Apr 3, 2013
Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference Apr 1, 2013
Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI) Mar 27, 2013
Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology Mar 21, 2013
FDA Approves Navidea’s Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Mapping Mar 13, 2013
Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 2013 Mar 4, 2013
